These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
272 related articles for article (PubMed ID: 30822543)
1. Phase-shifting of the transmissibility of macrolide-sensitive and resistant Mycoplasma pneumoniae epidemics in Hong Kong, from 2015 to 2018. Zhao S; Musa SS; Qin J; He D Int J Infect Dis; 2019 Apr; 81():251-253. PubMed ID: 30822543 [TBL] [Abstract][Full Text] [Related]
2. Emergence of Macrolide-Resistant Mycoplasma pneumoniae in Hong Kong Is Linked to Increasing Macrolide Resistance in Multilocus Variable-Number Tandem-Repeat Analysis Type 4-5-7-2. Ho PL; Law PY; Chan BW; Wong CW; To KK; Chiu SS; Cheng VC; Yam WC J Clin Microbiol; 2015 Nov; 53(11):3560-4. PubMed ID: 26338857 [TBL] [Abstract][Full Text] [Related]
3. Severe macrolide-resistant Mycoplasma pneumoniae pneumonia associated with macrolide failure. Cheong KN; Chiu SS; Chan BW; To KK; Chan EL; Ho PL J Microbiol Immunol Infect; 2016 Feb; 49(1):127-30. PubMed ID: 25556047 [TBL] [Abstract][Full Text] [Related]
4. Macrolide-Resistant Mycoplasma pneumoniae in the United States as Determined from a National Surveillance Program. Waites KB; Ratliff A; Crabb DM; Xiao L; Qin X; Selvarangan R; Tang YW; Zheng X; Dien Bard J; Hong T; Prichard M; Brooks E; Dallas S; Duffy L; Mixon E; Fowler KB; Atkinson TP J Clin Microbiol; 2019 Nov; 57(11):. PubMed ID: 31484701 [TBL] [Abstract][Full Text] [Related]
5. Killing kinetics of minocycline, doxycycline and tosufloxacin against macrolide-resistant Mycoplasma pneumoniae. Morozumi M; Okada T; Tajima T; Ubukata K; Iwata S Int J Antimicrob Agents; 2017 Aug; 50(2):255-257. PubMed ID: 28579455 [TBL] [Abstract][Full Text] [Related]
6. Rapid defervescence after doxycycline treatment of macrolide-resistant Mycoplasma pneumoniae-associated community-acquired pneumonia in children. Lung DC; Yip EK; Lam DS; Que TL Pediatr Infect Dis J; 2013 Dec; 32(12):1396-9. PubMed ID: 23817339 [TBL] [Abstract][Full Text] [Related]
7. Prevalence and Clinical Features of Community-Acquired Pneumonia Caused by Macrolide-Resistant Choi JH; Seong GM; Ko Y; Kim YR; Kim C Microb Drug Resist; 2019 May; 25(4):577-581. PubMed ID: 30484744 [No Abstract] [Full Text] [Related]
8. Therapeutic efficacy of azithromycin, clarithromycin, minocycline and tosufloxacin against macrolide-resistant and macrolide-sensitive Mycoplasma pneumoniae pneumonia in pediatric patients. Ishiguro N; Koseki N; Kaiho M; Ariga T; Kikuta H; Togashi T; Oba K; Morita K; Nagano N; Nakanishi M; Hara K; Hazama K; Watanabe T; Yamanaka T; Sasaki S; Furuyama H; Shibata M; Shida S; Ishizaka A; Tabata Y; Aoyagi H; Naito H; Yoshioka M; Horino A; Kenri T; PLoS One; 2017; 12(3):e0173635. PubMed ID: 28288170 [TBL] [Abstract][Full Text] [Related]
9. Molecular characterization and analysis of Mycoplasma pneumoniae among patients of all ages with community-acquired pneumonia during an epidemic in China. Qu J; Chen S; Bao F; Gu L; Cao B Int J Infect Dis; 2019 Jun; 83():26-31. PubMed ID: 30926541 [TBL] [Abstract][Full Text] [Related]
10. Macrolide resistance of Mycoplasma pneumoniae, South Korea, 2000-2011. Hong KB; Choi EH; Lee HJ; Lee SY; Cho EY; Choi JH; Kang HM; Lee J; Ahn YM; Kang YH; Lee JH Emerg Infect Dis; 2013 Aug; 19(8):1281-4. PubMed ID: 23876792 [TBL] [Abstract][Full Text] [Related]
11. Macrolide resistance of Jiang Y; Dou H; Xu B; Xu B; Zhou W; Wang H; Ge L; Hu Y; Han X; Qin X; Li J; Ye L; Wu L; Zuo H; Zhang Q; Liu L; Hu W; Shao J; Yin Q; Han L; Fu X; Dong X; Dong Y; Fu Y; Zhao M; Sun Q; Huo J; Liu D; Liu W; Li Y; Wang Y; Xin D; Shen K Epidemiol Infect; 2024 Apr; 152():e75. PubMed ID: 38634450 [TBL] [Abstract][Full Text] [Related]
12. Prevalence, genotyping and macrolide resistance of Mycoplasma pneumoniae among isolates of patients with respiratory tract infections, Central Slovenia, 2006 to 2014. Kogoj R; Mrvic T; Praprotnik M; Kese D Euro Surveill; 2015; 20(37):. PubMed ID: 26536357 [TBL] [Abstract][Full Text] [Related]
14. Assessment of variables associated with prolonged admission duration in children with Mycoplasma pneumoniae pneumonia. Sung M; Roh EJ; Lee ES; Lee JY; Kim HB; Ahn Y; Eun BW; Kim JK; Kim HY; Jung SS; Kim M; Kang EK; Yang EA; Lee SJ; Park Y; Seo JH; Lee E; Yang ES; Cho HM; Shin M; Chung HL; Jang YY; Choi BS; Kim H; Jung JA; You ST; Lee MH; Kim JT; Kim BS; Hwang YH; Shim JY; Yang HJ; Han MY; Yew HY; Kim DH; Jeong SO; Whang K; Lee E; Jeon YH; Chung EH Clin Respir J; 2022 Nov; 16(11):756-767. PubMed ID: 36205104 [TBL] [Abstract][Full Text] [Related]
19. Rising rates of macrolide-resistant Mycoplasma pneumoniae in the central United States. Yamada M; Buller R; Bledsoe S; Storch GA Pediatr Infect Dis J; 2012 Apr; 31(4):409-0. PubMed ID: 22209916 [TBL] [Abstract][Full Text] [Related]
20. Emergence of macrolide-resistant strains during an outbreak of Mycoplasma pneumoniae infections in children. Chironna M; Sallustio A; Esposito S; Perulli M; Chinellato I; Di Bari C; Quarto M; Cardinale F J Antimicrob Chemother; 2011 Apr; 66(4):734-7. PubMed ID: 21393214 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]